ArticleMolecular cancer therapeutics2022
Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.British journal of cancer · 2026Review
- Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.Cancer research · 2026Article
- Review
- Review
- Efficacy of larotrectinib in pediatric cancers withTranslational pediatrics · 2025Article
- Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls.International journal of molecular sciences · 2025Review
- Advances and challenges in human 3D solid tumor models.Advanced functional materials · 2025Article
- ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity.Molecular cancer research : MCR · 2025Article
- Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Molecular Basis of Breast Tumor Heterogeneity.Advances in experimental medicine and biology · 2025Review
- Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors.Translational oncology · 2024Article
- What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?Current treatment options in oncology · 2024Review
- Targeting RAF dimers in RAS mutant tumors: From biology to clinic.Acta pharmaceutica Sinica. B · 2024Review
- Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma.Cancers · 2023Review
- Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance.Science advances · 2023Article
- The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.Molecular cancer therapeutics · 2023Article
- Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study.Journal of neuro-oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Natalia GarciaGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas.
Vanessa Del PozoGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas.
Marielle E YohePediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-5356-9426
Craig M GoodwinLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-1293-2334
Terry J ShacklefordGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas.ORCID 0000-0002-3621-2289
Long WangGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas.
Kunal BaxiGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas.ORCID 0000-0001-6094-6410
Yidong ChenGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas.ORCID 0000-0001-6806-2185
Anna T RogojinaGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas.
Sara M ZimmermanGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Cody J PeerGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-9395-3473
William D FiggGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0003-2428-5613
Myron S IgnatiusGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas.
Kris C WoodDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.ORCID 0000-0002-5887-2253
Peter J HoughtonGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas.
Angelina V VasevaGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, Texas. vaseva@uthscsa.edu.ORCID 0000-0003-4823-9080
The University of Texas Health Science Center at San Antonio · USNational Cancer Institute · USDuke University · USUniversity of North Carolina at Chapel Hill · US
Funding
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1MInstitute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR002645 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2018 to 2022
$20.4MXENOGRAFT AND CELL LINE COREP01CA165995 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HOUGHTON, PETER J · 2013 to 2017
$7.9MScreening for Cys-Reactive Ligands to Target PAX3-FOXO1U54CA231630 · NCI · DUKE UNIVERSITY · PI COUNTER, CHRISTOPHER M, LINARDIC, CORINNE MARY · 2019 to 2023
$6.5MPediatric Preclinical Testing Consortium: Research Programs Non-CNS (U01)U01CA199297 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HOUGHTON, PETER J · 2015 to 2021
$3.5MCancer Biology Training ProgramT32CA148724 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Pei Wang, Feng-Chun Yang · 2011 to 2026
$3.3MA Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver CancerU01CA263981 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Raushan Kurmasheva · 2021 to 2026
$3.2MSelectively targeting apoptosis in PIK3CA mutant colorectal cancersR01CA207083 · NCI · DUKE UNIVERSITY · PI WOOD, KRIS C. · 2016 to 2020
$1.8MHigh Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
$600kNCATS NIH HHS UL1 TR002645NCI NIH HHS P01 CA165995NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA207083NCI NIH HHS T32 CA148724NCI NIH HHS U01 CA199297NCI NIH HHS U01 CA263981NCI NIH HHS U54 CA231630NIH HHS S10 OD021805
Abstract
Oncogenic RAS signaling is an attractive target for fusion-negative rhabdomyosarcoma (FN-RMS). Our study validates the role of the ERK MAPK effector pathway in mediating RAS dependency in a panel of
Indexed as
AnimalsApoptosisCell DifferentiationCell Line, TumorCell ProliferationExtracellular Signal-Regulated MAP KinasesFemaleGenes, rasHumansMAP Kinase Signaling SystemMiceProto-Oncogene Proteins B-rafRhabdomyosarcomaTransfectionExtracellular Signal-Regulated MAP KinasesProto-Oncogene Proteins B-raf
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.